Dihydrofolate reductase (DHFR) is an enzyme that catalyzes the reduction of dihydrofolate (DHF) to tetrahydrofolate (THF). Chemotherapy drugs such as methotrexate help to slow the progression of cancer by limiting the ability of dividing cells to make nucleotides by competitively inhibiting DHFR. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been previously reported to exhibit competitive inhibition of DHFR, in addition to their primary action on cyclooxygenase enzymes. This interaction interferes with the enzymatic reduction of dihydrofolate to tetrahydrofolate, thereby impeding the folate metabolism pathway essential for nucleotide synthesis and cell proliferation. This activity stems from their structural resemblance to the p-aminobenzoyl-l-glutamate (pABG) moiety of folate, a substrate of DHFR. It has been established that NSAIDs containing a salicylate group (which has structural similarities to pABG), such as diflunisal, exhibit stronger DHFR-binding activity. In this study, we synthesized salicylate derivatives of naproxen with the aim of exploring their potential as inhibitors of DHFR. The interactions between these derivatives and human DHFR were characterized using a combination of biochemical, biophysical, and structural methods. Through polyacrylamide gel electrophoresis (PAGE) analysis, enzymatic assays, and quantitative ELISA, we investigated the binding affinity and inhibitory potency of the synthesized salicylate derivatives towards DHFR. The findings of this study suggest the potential of salicylate derivatives of naproxen as promising candidates for the inhibition of DHFR, thereby offering novel therapeutic opportunities for modulating the inflammatory process through multiple pathways. Further optimization of these derivatives could lead to the development of more efficacious dual-targeted analogs with enhanced therapeutic benefits.
References
[1]
Wróbel, A., Baradyn, M., Ratkiewicz, A. and Drozdowska, D. (2021) Synthesis, Biological Activity, and Molecular Dynamics Study of Novel Series of a Trimethoprim Analogs as Multi-Targeted Compounds: Dihydrofolate Reductase (DHFR) Inhibitors and DNA-Binding Agents. International Journal of Molecular Sciences, 22, Article 3685. https://doi.org/10.3390/ijms22073685
[2]
Ozaki, Y., King, R.W. and Carey, P.R. (1981) Methotrexate and Folate Binding to Dihydrofolate Reductase. Separate Characterization of the Pteridine and P-Aminobenzoyl Binding Sites by Resonance Raman Spectroscopy. Biochemistry, 20, 3219-3225. https://doi.org/10.1021/bi00514a036
[3]
Bowden, K., Hall, A.D., Birdsall, B., Feeney, J. and Roberts, G.C.K. (1989) Interactions between Inhibitors of Dihydrofolate Reductase. Biochemical Journal, 258, 335-342. https://doi.org/10.1042/bj2580335
[4]
Selhub, J., Dhar, G.J. and Rosenberg, I.H. (1978) Inhibition of Folate Enzymes by Sulfasalazine. Journal of Clinical Investigation, 61, 221-224. https://doi.org/10.1172/jci108921
[5]
Baggott, J.E., Morgan, S.L., Ha, T., Vaughn, W.H. and Hine, R.J. (1992) Inhibition of Folate-Dependent Enzymes by Non-Steroidal Anti-Inflammatory Drugs. Biochemical Journal, 282, 197-202. https://doi.org/10.1042/bj2820197
[6]
Duff, M.R., Gabel, S.A., Pedersen, L.C., DeRose, E.F., Krahn, J.M., Howell, E.E., et al. (2020) The Structural Basis for Nonsteroidal Anti-Inflammatory Drug Inhibition of Human Dihydrofolate Reductase. Journal of Medicinal Chemistry, 63, 8314-8324. https://doi.org/10.1021/acs.jmedchem.0c00546
[7]
Lawrence, V.A., Loewenstein, J.E. and Eichner, E.R. (1984) Aspirin and Folate Binding: In vivo and in vitro Studies of Serum Binding and Urinary Excretion of Endogenous Folate. The Journal of Laboratory and Clinical Medicine, 103, 944-948.
[8]
Kolawole, O.R. and Kashfi, K. (2022) NSAIDs and Cancer Resolution: New Paradigms beyond Cyclooxygenase. International Journal of Molecular Sciences, 23, Article 1432. https://doi.org/10.3390/ijms23031432
[9]
Brogden, R.N., Pinder, R.M., Sawyer, P.R., Speight, T.M. and Avery, G.S. (1975) Naproxen: A Review of Its Pharmacological Properties and Therapeutic Efficacy and Use. Drugs, 9, 326-363. https://doi.org/10.2165/00003495-197509050-00002
[10]
Zheng, J., Rubin, E.J., Bifani, P., Mathys, V., Lim, V., Au, M., et al. (2013) Para-Aminosalicylic Acid Is a Prodrug Targeting Dihydrofolate Reductase in Mycobacterium Tuberculosis. Journal of Biological Chemistry, 288, 23447-23456. https://doi.org/10.1074/jbc.m113.475798
[11]
Raimondi, M.V., Randazzo, O., La Franca, M., Barone, G., Vignoni, E., Rossi, D., et al. (2019) DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents. Molecules, 24, Article 1140. https://doi.org/10.3390/molecules24061140
[12]
National Institute of Standards and Technology (2023) Salicylic Acid. https://webbook.nist.gov/cgi/cbook.cgi?ID=C69727&Type=IR-SPEC&Index=2
[13]
Dharmalingam, S.R., Chidambaram, K., Ramamurthy, S. and Nadaraju, S. (2014) Effects of Nanosuspension and Inclusion Complex Techniques on the in vitro Protease Inhibitory Activity of Naproxen. Brazilian Journal of Pharmaceutical Sciences, 50, 165-171. https://doi.org/10.1590/s1984-82502011000100017
[14]
Protein Expression and Purification Series. https://www.bio-rad.com/webroot/web/pdf/lse/literature/pepsi_hr_1665067.pdf
[15]
Leamon, C.P. and Low, P.S. (1991) Delivery of Macromolecules into Living Cells: A Method That Exploits Folate Receptor Endocytosis. Proceedings of the National Academy of Sciences, 88, 5572-5576. https://doi.org/10.1073/pnas.88.13.5572
[16]
El-Dershaby, N.H., El-Hawash, S.A., Kassab, S.E., Daabees, H.G., Abdel Moneim, A.E. and El-Miligy, M.M.M. (2022) Rational Design and Synthesis of New Selective COX-2 Inhibitors with in vivo PGE2-Lowering Activity by Tethering Benzenesulfonamide and 1,2,3-Triazole Pharmacophores to Some Nsaids. Pharmaceuticals, 15, Article 1165. https://doi.org/10.3390/ph15101165
[17]
Assaraf, Y.G., Leamon, C.P. and Reddy, J.A. (2014) The Folate Receptor as a Rational Therapeutic Target for Personalized Cancer Treatment. Drug Resistance Updates, 17, 89-95. https://doi.org/10.1016/j.drup.2014.10.002
[18]
Haroon, F., Farwa, U., Arif, M., Raza, M.A., Sandhu, Z.A., El Oirdi, M., et al. (2023) Novel Para-Aminobenzoic Acid Analogs and Their Potential Therapeutic Applications. Biomedicines, 11, Article 2686. https://doi.org/10.3390/biomedicines11102686